LL-37 vs TB-500
Research Verdict
LL-37 is the stronger research reference for the stated comparison criteria. LL-37 has the stronger human biology evidence; direct TB-500 fragment evidence remains preclinical.
Quick Answers
Which is better, LL-37 or TB-500?
LL-37 is the stronger research reference for the stated comparison criteria. LL-37 has the stronger human biology evidence; direct TB-500 fragment evidence remains preclinical.
What is the key difference between LL-37 and TB-500?
LL-37 is an antimicrobial and immunomodulatory peptide. TB-500 fragment 17-23 is studied for repair signaling, but its full human mechanism is not established.
Evidence Comparison
LL-37 has strong human observational and mechanistic evidence as an endogenous host-defense peptide, although exogenous therapy remains investigational. Direct TB-500 fragment evidence is preclinical; RegeneRx Phase 2 trials tested full-length thymosin beta-4, not fragment 17-23.
Evidence Context Favoring LL-37
Antimicrobial research, biofilm disruption, or innate immunity studies.
Evidence Context Favoring TB-500
Preclinical tendon-healing research where the 2026 TB-500 rat study is directly relevant.
Side-by-Side Snapshot
| Evidence grade | LL-37: Level C TB-500: Level C |
|---|---|
| Research status | LL-37: Phase 1 TB-500: Preclinical |
| Primary category | LL-37: Immune Support TB-500: Healing & Recovery |
| Cited studies | LL-37: 2 TB-500: 9 |